

LGALS3 Mouse

Description: LGALS3 Mouse Recombinant produced in E. coli is a single polypeptide chain containing 287 amino acids (1-264) and having a molecular mass of 29.8 kDa. LGALS3 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Catalog #: CYPs-195

For research use only.

Synonyms: CBP35, GAL3, GALBP, GALIG, LGALS2, MAC2, Galectin-3, Lectin, galactose binding, soluble 3, Lectin, galactose binding, soluble 3, isoform CRA_a, Lectin, galactose binding, soluble 3, isoform CRA_d, Lgals3.

Source: E.coli.

Physical Appearance: Sterile Filtered colorless solution.

Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MGSMADSFSL NDALAGSGNP
NPQGYPGAWG NQPGAGGYPG AAYPGAYPGQ APPGAYPGQA PPGAYPGQAP
PSAYPGPTAP GAYPGPTAPG AYPGSTAPGA FPGQPGAPGA YPSAPGGYPA AGPYGVPA GP
LTPYDLPLP GGVMRMLIT IMGTVKPNAN RIVLDFRRGN DVAHFHNPFR NENRRRVIVC
NTKQDNNWGK EERQSAPFFE SG

Purity: Greater than 95% as determined by SDS-PAGE.

Formulation:

The LGALS3 solution (0.5mg/1ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 50% glycerol, 1mM DTT and 2mM EDTA.

Stability:

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

Usage:

NeoBiolab's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Introduction:

Galectin-3 mediates with the alpha-3, beta-1 integrin the stimulation by cspg4 of endothelial cells migration. Galectin-3 plays an necessary part during the acquisition of vasculogenic mimicry and angiogenic properties associated with melanoma progression. LGALS3 overexpression is highly expressed in early stages of papillary carcinoma, and its expression intensity declines during tumor progression. Serum levels of LGALS3 are high in patients with thyroid malignancy but there is considerable overlap in serum LGALS3 concentrations between those with benign and malignant nodular thyroid disease. LGLAS3 takes part as an immune regulator to inhibit T-cell immune responses and promote tumor growth, as a result providing a new mechanism for tumor immune tolerance.

To place an order, please [Click HERE](#).